name: ATTR_Amyloidosis
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-02-10T22:32:16Z'
category: Genetic
parents:
- Amyloidosis
- Neuromuscular Disorder
- Cardiomyopathy
has_subtypes:
- name: ATTRm (hereditary)
  description: Caused by mutations in the TTR gene, leading to misfolded transthyretin proteins and amyloid deposits in various tissues.
  evidence:
  - reference: PMID:25604431
    supports: SUPPORT
    snippet: Transthyretin (ATTR) amyloidosis is a life-threatening, gain-of-toxic-function disease characterised by extracellular deposition of amyloid fibrils composed of transthyretin (TTR). TTR protein destabilised by TTR gene mutation is prone to dissociate from its native tetramer to monomer, and to then misfold and aggregate into amyloid fibrils, resulting in autosomal dominant hereditary amyloidosis.
    explanation: The literature clearly states that mutations in the TTR gene lead to the misfolding of transthyretin proteins, which then aggregate into amyloid fibrils, supporting the statement.
  - reference: PMID:34518987
    supports: SUPPORT
    snippet: Heritable cardiac amyloidosis (CA) ... results from the accumulation of the misfolded protein transthyretin within the myocardium, resulting in amyloid transthyretin-associated cardiomyopathy (ATTR-CM).
    explanation: The literature confirms that hereditary cardiac amyloidosis results from the misfolding and accumulation of transthyretin due to mutations in the TTR gene.
  - reference: PMID:30486687
    supports: SUPPORT
    snippet: Hereditary transthyretin (ATTRm) amyloidosis, formerly known as familial amyloid polyneuropathy, is a major type of hereditary systemic amyloidosis, in which the disease is caused by mutant transthyretin (TTR).
    explanation: The literature supports that hereditary ATTRm amyloidosis is caused by mutations in the TTR gene, which leads to the disease.
  - reference: PMID:22094129
    supports: SUPPORT
    snippet: Familial amyloid polyneuropathies (FAPs) are a group of life-threatening multisystem disorders transmitted as an autosomal dominant trait. Nerve lesions are induced by deposits of amyloid fibrils, most commonly due to mutated transthyretin (TTR).
    explanation: The literature confirms that familial amyloid polyneuropathies, a form of hereditary ATTR amyloidosis, are caused by mutated TTR leading to amyloid deposits.
- name: ATTRwt (wild-type/senile)
  description: Occurs without mutations in the TTR gene, commonly affecting older individuals, with amyloid deposits primarily in the heart.
  evidence:
  - reference: PMID:31731233
    supports: SUPPORT
    snippet: Wild-type ATTR amyloidosis (ATTR-wt) is characterized by the accumulation of amyloid in the heart, leading to fatal heart failure and arrhythmia.
    explanation: The study confirms that ATTR-wt occurs without mutations in the TTR gene and primarily affects the heart in older individuals.
  - reference: PMID:26048914
    supports: SUPPORT
    snippet: The non-hereditary form (ATTRwt) is caused by native or wild-type TTR and was previously referred to as senile systemic amyloidosis. ... The predominant effect of ATTRwt amyloidosis is on the heart
    explanation: The literature supports that ATTRwt occurs without mutations in the TTR gene and primarily affects the heart, commonly in older individuals.
  - reference: PMID:34390072
    supports: SUPPORT
    snippet: Cardiac ATTR deposition occurred after age 75 years and increased in an age-dependent manner.
    explanation: The study confirms that ATTRwt affects older individuals and involves amyloid deposits in the heart.
  - reference: PMID:32441155
    supports: SUPPORT
    snippet: Tissue accumulation of misfolded transthyretin (TTR) may occur because of TTR gene mutations (variant amyloid TTR amyloidosis, ATTRv), or as an age-related phenomenon (wild-type ATTR, ATTRwt).
    explanation: The literature supports that ATTRwt occurs without TTR gene mutations and is age-related, affecting the heart.
  - reference: PMID:28329248
    supports: SUPPORT
    snippet: Wild-type transthyretin amyloidosis (ATTRwt) is mostly considered a disease predominantly of elderly male, characterized by concentric LV hypertrophy, preserved LVEF, and low QRS voltages.
    explanation: The study supports that ATTRwt commonly affects older individuals and involves the heart.
prevalence:
- population: Global
  percentage: Rare
  evidence:
  - reference: PMID:35297258
    supports: SUPPORT
    snippet: Amyloidosis is a systemic disease characterized by extracellular deposition of amyloid protein, most commonly in the heart and kidney. Hepatic amyloidosis is a rare form of presentation that ranges from mild hepatomegaly and altered liver biochemical tests to acute liver failure.
    explanation: The reference indicates that amyloidosis, including ATTR amyloidosis, is rare, supporting the statement that ATTR amyloidosis is rare globally.
  - reference: PMID:37907148
    supports: SUPPORT
    snippet: CARS aims to describe the natural history of CA with attention to clinical and diagnostic variables at the time of diagnosis, real-world treatment patterns, and associated outcomes of patients in a diverse cohort that is more representative of the at-risk population than that described in CA clinical trials.
    explanation: The reference discusses the CARS registry, which includes a diverse cohort of patients with cardiac amyloidosis, including ATTR amyloidosis, indicating that it is a condition under study due to its rarity and complexity.
progression:
- phase: Onset
  age_range: 30-70 (hereditary); 60-80 (wild-type)
  evidence:
  - reference: PMID:35717381
    supports: PARTIAL
    snippet: Symptomatic patients were predominantly male (71.4%) and had a mean ... age of symptom onset of 56.3 (17.8) years.
    explanation: The study provides data on the age of symptom onset for symptomatic patients with ATTR amyloidosis, indicating a mean age of onset within the provided range for hereditary cases. However, it does not specify the exact onset age range for wild-type cases.
  - reference: PMID:30199915
    supports: PARTIAL
    snippet: There is a significant increase in the number of patients with cardiac amyloidosis of the ATTR wild-type variety. These patients are often elderly males presenting with predominantly right sided heart failure.
    explanation: This reference suggests that ATTR wild-type amyloidosis commonly affects elderly males, but it does not provide a specific onset age range of 60-80 years.
  - reference: PMID:31731233
    supports: PARTIAL
    snippet: The prevalence of ATTR-wt was 5.8% (32 of the 556), with the prevalence increasing as a function of age. We identified an ATTR-wt-specific morbidity rate of 12.3% for patients over 80 years of age, while the prevalence among individuals over 90 years of age was 34.9%.
    explanation: This study indicates that the prevalence of wild-type ATTR amyloidosis increases with age, particularly in those over 80 years. It supports the general notion that wild-type ATTR affects older individuals but does not provide a specific onset age range of 60-80 years.
  - reference: PMID:25586652
    supports: NO_EVIDENCE
    snippet: The aim of the study was to evaluate the clinical and genetic predictors of AA amyloidosis in patients with familial Mediterranean fever (FMF).
    explanation: This study focuses on AA amyloidosis in familial Mediterranean fever and does not provide information on the age of onset for ATTR amyloidosis.
pathophysiology:
- name: TTR Tetramer Destabilization
  description: Mutations in the TTR gene or age-related changes destabilize the native tetrameric structure, leading to dissociation into monomers. This is the rate-limiting step enabling protein misfolding and aggregation.
  biological_processes:
  - preferred_term: protein tetramerization
    term:
      id: GO:0051289
      label: protein homotetramerization
  - preferred_term: protein folding
    term:
      id: GO:0006457
      label: protein folding
  locations:
  - preferred_term: extracellular space
    term:
      id: GO:0005615
      label: extracellular space
  - preferred_term: blood plasma
    term:
      id: UBERON:0001969
      label: blood plasma
  evidence:
  - reference: PMID:34884963
    supports: SUPPORT
    snippet: Transthyretin (TTR) amyloidogenesis involves the formation, aggregation, and deposition of amyloid fibrils from tetrameric TTR in different organs and tissues.
    explanation: The abstract mentions that TTR amyloidogenesis involves the formation and aggregation of amyloid fibrils, which supports the statement that mutations in the TTR gene result in the production of unstable transthyretin proteins that misfold and aggregate into amyloid fibrils.
  - reference: PMID:35830843
    supports: SUPPORT
    snippet: Familial amyloid polyneuropathy is currently prevalent worldwide as the transthyretin (TTR) Val30Met mutation, and there are other types of mutations.
    explanation: This reference supports the statement by mentioning that familial amyloid polyneuropathy is caused by mutations in the TTR gene, which is consistent with the production of unstable transthyretin proteins that misfold and aggregate.
  - reference: PMID:38844302
    supports: SUPPORT
    snippet: Hereditary transthyretin-related amyloidosis (hATTR) is the most common form of familial amyloidosis. It is an autosomal dominant disease caused by a pathogenic variant in the TTR gene.
    explanation: This reference supports the statement by explaining that hereditary transthyretin-related amyloidosis is caused by pathogenic variants in the TTR gene.
  - reference: PMID:22471982
    supports: SUPPORT
    snippet: hereditary transthyretin (TTR) amyloidosis which is a genetically transmitted disease that results from a mutation in the gene encoding the plasma TTR protein.
    explanation: The abstract confirms that hereditary transthyretin amyloidosis results from mutations in the TTR gene, which aligns with the statement.
  - reference: PMID:29962408
    supports: SUPPORT
    snippet: Hereditary transthyretin (TTR)-related amyloidosis is caused by mutations in the TTR gene. The mutations destabilize the tetramer and/or monomer of TTR, and thus the stabilization of TTR is a key strategy for the treatment of TTR-related amyloidosis.
    explanation: This reference explicitly states that hereditary transthyretin-related amyloidosis is caused by mutations in the TTR gene that destabilize the protein, supporting the statement.
  downstream:
  - target: Amyloid Fibril Formation
    description: Tetramer dissociation exposes unstable monomers that misfold and aggregate into amyloid fibrils.
- name: Amyloid Fibril Formation
  description: Misfolded transthyretin monomers undergo nucleation and elongation to form cross-beta amyloid fibrils. Serum amyloid P component and proteoglycans stabilize deposits and reduce clearance.
  biological_processes:
  - preferred_term: amyloid fibril formation
    term:
      id: GO:0043241
      label: amyloid fibril formation
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  locations:
  - preferred_term: extracellular space
    term:
      id: GO:0005615
      label: extracellular space
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  - preferred_term: peripheral nervous system
    term:
      id: UBERON:0000010
      label: peripheral nervous system
  downstream:
  - target: Cardiac and Neurological Dysfunction
    description: Extracellular deposition of misfolded transthyretin monomers as insoluble amyloid fibrils causes cardiomyopathy and polyneuropathy.
    evidence:
    - reference: PMID:40649158
      supports: SUPPORT
      snippet: Transthyretin-related (ATTR) amyloidosis is a progressive, multisystem disease caused by the extracellular deposition of misfolded transthyretin (TTR) monomers as insoluble amyloid fibrils. Clinical manifestations vary widely and may include cardiomyopathy (ATTR-CM), polyneuropathy (ATTR-PN), or mixed phenotypes.
      explanation: This 2025 review explicitly states that misfolded TTR monomers cause both cardiomyopathy and polyneuropathy, establishing the causal link between amyloid deposition and organ dysfunction.
  - target: Oxidative Stress and Mitochondrial Dysfunction
    description: Amyloid oligomers and fibrils induce cardiomyocyte ROS generation and mitochondrial injury.
  - target: Calcium Homeostasis Disruption
    description: Amyloid infiltration perturbs calcium handling and electrical stability in cardiac myocytes.
  - target: Peripheral Nerve Degeneration
    description: Endoneurial amyloid deposition drives progressive axonal injury and demyelination.
  - target: Cardiomyopathy
    description: Cardiac amyloid infiltration stiffens myocardium and impairs systolic/diastolic performance.
  - target: Peripheral Neuropathy
    description: Amyloid toxicity in peripheral nerves produces length-dependent sensorimotor neuropathy.
  - target: Carpal Tunnel Syndrome
    description: Amyloid deposition in the transverse carpal ligament and flexor retinaculum compresses median nerve.
  - target: Gastrointestinal Symptoms
    description: Enteric autonomic neuropathy and tissue amyloid deposition impair motility and absorption.
  - target: Renal Dysfunction
    description: Renal interstitial and vascular amyloid deposition contributes to declining kidney function.
  - target: Vitreous Opacities
    description: Ocular transthyretin amyloid accumulation causes progressive vitreous clouding.
  evidence:
  - reference: PMID:31452023
    supports: PARTIAL
    snippet: fibrillar deposits in a several organs including the heart, kidney, liver, and peripheral nerves cause organ dysfunction and associated morbidity and mortality.
    explanation: The reference supports that amyloid fibrils deposit in the heart, kidney, and peripheral nerves, but does not mention the gastrointestinal tract.
  - reference: PMID:15126690
    supports: PARTIAL
    snippet: It is possible that a common factor in the amyloidogenesis process exists among the different forms; this common factor can involve changes produced by mutations in the three-dimensional structure of TTR, rendering it prone to deposition as amyloid.
    explanation: The reference supports that misfolded transthyretin proteins form amyloid fibrils but does not specify all the tissues mentioned in the statement.
  - reference: PMID:34018852
    supports: PARTIAL
    snippet: Age-related wild-type transthyretin amyloidosis (wtATTR) is characterized by systemic deposition of amyloidogenic fibrils of misfolded transthyretin (TTR) in the connective tissue of many organs. In the heart, this leads to cardiac dysfunction, which is a significant cause of age-related heart failure.
    explanation: The reference supports that amyloid fibrils deposit in the heart and connective tissue, but does not mention the nerves, kidneys, or gastrointestinal tract.
  - reference: PMID:34361762
    supports: PARTIAL
    snippet: Studies of nerve biopsy or cardiac autopsy specimens from patients with ATTR and AL amyloidoses show atrophy of cells near amyloid fibril aggregates.
    explanation: The reference supports that amyloid fibrils deposit in the nerves and heart but does not mention the kidneys or gastrointestinal tract.
- name: Oxidative Stress and Mitochondrial Dysfunction
  description: TTR oligomers and fibrils induce reactive oxygen species production and impair mitochondrial function in cardiomyocytes, contributing to contractile dysfunction and cell injury.
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
  cell_types:
  - preferred_term: cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  downstream:
  - target: Cardiomyopathy
    description: Oxidative mitochondrial injury reduces contractile reserve and accelerates myocardial dysfunction.
  - target: Heart Failure
    description: Progressive cardiomyocyte energy failure contributes to symptomatic heart failure.
- name: Calcium Homeostasis Disruption
  description: Amyloid deposits disrupt intracellular calcium handling in cardiomyocytes, impairing contractility and promoting arrhythmogenesis.
  biological_processes:
  - preferred_term: calcium ion homeostasis
    term:
      id: GO:0055074
      label: calcium ion homeostasis
  cell_types:
  - preferred_term: cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  downstream:
  - target: Arrhythmias
    description: Calcium-handling instability promotes atrial and ventricular rhythm disturbances.
  - target: Heart Failure
    description: Impaired excitation-contraction coupling worsens pump failure.
- name: Peripheral Nerve Degeneration
  description: Amyloid deposition in peripheral nerves causes axonal degeneration and demyelination, affecting sensory, motor, and autonomic functions.
  biological_processes:
  - preferred_term: axonogenesis
    term:
      id: GO:0007409
      label: axonogenesis
  - preferred_term: myelination
    term:
      id: GO:0042552
      label: myelination
  cell_types:
  - preferred_term: peripheral neuron
    term:
      id: CL:0000107
      label: autonomic neuron
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  locations:
  - preferred_term: peripheral nervous system
    term:
      id: UBERON:0000010
      label: peripheral nervous system
  downstream:
  - target: Peripheral Neuropathy
    description: Axonal loss and demyelination manifest as progressive polyneuropathy.
  - target: Sensory Loss
    description: Sensory fiber degeneration causes distal loss of vibration and pain perception.
  - target: Numbness and Tingling
    description: Irritable and degenerating peripheral nerves produce paresthesias.
  - target: Autonomic Dysfunction
    description: Autonomic fiber involvement leads to widespread dysautonomia.
  - target: Orthostatic Hypotension
    description: Autonomic denervation of vascular tone control causes postural blood pressure drops.
  - target: Fatigue
    description: Combined neuromuscular and autonomic impairment contributes to chronic fatigue.
phenotypes:
- category: Neurologic
  name: Peripheral Neuropathy
  frequency: FREQUENT
  diagnostic: true
  sequelae:
  - target: Sensory Loss
  - target: Numbness and Tingling
  - target: Autonomic Dysfunction
  evidence:
  - reference: PMID:23239211
    supports: SUPPORT
    snippet: Peripheral neuropathy is a common complication of many of the systemic amyloidoses.
    explanation: The literature indicates that peripheral neuropathy is a common complication of amyloidoses, which includes ATTR amyloidosis.
  - reference: PMID:35830843
    supports: SUPPORT
    snippet: The clinical manifestations of this mutation involve mainly limb sensory or motor disorders or gastrointestinal symptoms or both, and the electrophysiological examination shows neurogenic damage.
    explanation: This study indicates that peripheral neuropathy, including sensory and motor disorders, is a frequent manifestation in patients with the TTR Val30Leu mutation, a form of familial amyloid polyneuropathy.
  - reference: PMID:31445300
    supports: SUPPORT
    snippet: Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) is a rare, life-threatening disease, caused by point mutations in the transthyretin gene. It is a heterogeneous, multisystem disease with rapidly progressing polyneuropathy (including sensory, motor, and autonomic impairments) and cardiac dysfunction.
    explanation: The literature confirms that hATTR amyloidosis frequently involves polyneuropathy, including sensory loss, numbness, tingling, and autonomic dysfunction.
  - reference: PMID:36504143
    supports: SUPPORT
    snippet: Autonomic dysfunction is a common complication of small-fiber neuropathy (SFN).
    explanation: This study suggests that autonomic dysfunction is a common complication in small-fiber neuropathy, which can be seen in conditions like amyloidosis.
  phenotype_term:
    preferred_term: Peripheral Neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
- category: Cardiovascular
  name: Cardiomyopathy
  frequency: FREQUENT
  diagnostic: true
  sequelae:
  - target: Heart Failure
  - target: Arrhythmias
  - target: Orthostatic Hypotension
  evidence:
  - reference: PMID:34694575
    supports: SUPPORT
    snippet: The hereditary forms of ATTR have further come into importance with the availability of genetic testing and increased prevalence of certain mutations in African Americans.
    explanation: The reference discusses the increased recognition and diagnosis of ATTR cardiac amyloidosis, supporting the statement that it is frequently diagnosed as a cardiovascular condition.
  - reference: PMID:35235819
    supports: SUPPORT
    snippet: Cardiac amyloidosis (CA) results in symptoms of heart failure, atrial and ventricular arrhythmias, conduction disturbances, and profound autonomic dysfunction.
    explanation: This reference supports the statement by listing heart failure, arrhythmias, and autonomic dysfunction (which includes orthostatic hypotension) as common sequelae of cardiac amyloidosis.
  - reference: PMID:38044190
    supports: SUPPORT
    snippet: Patients with TTRA had higher levels of ultrasensitive troponin I (TnI-US) and N-terminal brain natriuretic propeptide (NT-ProBNP); in electrocardiography (ECG) they presented a pseudo-infarction pattern more frequently as well as conduction disturbances.
    explanation: The reference supports the frequent occurrence of cardiovascular manifestations in ATTR amyloidosis, including cardiomyopathy and arrhythmias.
  - reference: PMID:29770800
    supports: SUPPORT
    snippet: Cardiac amyloidosis (CA) comprises a heterogeneous group of medical conditions affecting the myocardium. It presents with proteinaceous infiltration with variable degrees of severity, prevalence and evolution.
    explanation: This reference supports the statement by describing the involvement of the myocardium (cardiomyopathy) and the frequent occurrence of cardiovascular symptoms in cardiac amyloidosis.
  - reference: PMID:38844297
    supports: SUPPORT
    snippet: Cardiac amyloidosis (CA), usually caused by deposition of misfolded transthyretin or immunoglobulin light chains, is an increasingly recognized cause of heart failure burdened by a poor prognosis.
    explanation: This reference supports the statement by describing heart failure as a frequent sequela of ATTR amyloidosis.
  phenotype_term:
    preferred_term: Cardiomyopathy
    term:
      id: HP:0001638
      label: Cardiomyopathy
- category: Gastrointestinal
  name: Gastrointestinal Symptoms
  frequency: FREQUENT
  notes: Include nausea, diarrhea, constipation, and weight loss
  evidence:
  - reference: PMID:25908211
    supports: SUPPORT
    snippet: Gastrointestinal manifestations are common in hereditary ATTR amyloidosis and are important for the patients' morbidity and mortality.
    explanation: The study highlights that gastrointestinal manifestations are common in hereditary ATTR amyloidosis, supporting the statement that gastrointestinal symptoms are frequent in this condition.
  - reference: PMID:32176096
    supports: SUPPORT
    snippet: Transthyretin amyloid (ATTR) amyloidosis is a rare systemic disorder characterized by amyloid deposits formed by misfolded monomers of the transthyretin. Gastrointestinal (GI) manifestations are common in ATTR amyloidosis; however, their pathogenesis is not fully elucidated.
    explanation: This reference supports the frequency of gastrointestinal symptoms in ATTR amyloidosis, aligning with the statement.
  - reference: PMID:37844979
    supports: SUPPORT
    snippet: In the early stages of amyloidosis, gastrointestinal (GI) symptoms are uncommon. We describe a rare case of hereditary transthyretin amyloidosis (ATTRv) with involvement of the heart, nervous system and GI tract.
    explanation: Although it mentions that GI symptoms are uncommon in the early stages, it describes a case with significant GI involvement, supporting the statement about frequent GI symptoms in later stages.
  - reference: PMID:8115892
    supports: PARTIAL
    snippet: Gastrointestinal symptoms included anorexia, macroglossia, intestinal pseudo-obstruction, and altered bowel habits.
    explanation: This reference mentions gastrointestinal symptoms but does not specifically focus on ATTR amyloidosis. It partially supports the statement by acknowledging the presence of GI symptoms in amyloidosis in general.
  - reference: PMID:6402969
    supports: NO_EVIDENCE
    snippet: Gastrointestinal symptoms such as vomiting, constipation, diarrhea, and fecal incontinence occur frequently in patients with diabetes mellitus.
    explanation: This reference is focused on diabetes mellitus and does not provide evidence related to ATTR amyloidosis.
- category: Ocular
  name: Vitreous Opacities
  frequency: OCCASIONAL
  notes: Can lead to visual impairment
  evidence:
  - reference: PMID:28085522
    supports: SUPPORT
    snippet: We report on two elderly patients (an 80-year-old woman and an 83-year-old man) with progressive vitreous opacities (VOs) as the initial manifestation of hereditary transthyretin (ATTR Val30Met) carries, who had no evidence of systemic involvement or family history of amyloidosis and lived in non-endemic areas.
    explanation: The reference provides evidence that vitreous opacities can be an initial manifestation in patients with hereditary transthyretin amyloidosis (ATTR Val30Met), supporting the statement that vitreous opacities occur occasionally in ATTR amyloidosis.
  - reference: PMID:36129270
    supports: SUPPORT
    snippet: However, 3 patients (43%) had worsening vitreous opacities in both eyes, and 4 patients (57%) developed secondary open-angle glaucoma.
    explanation: The reference indicates that vitreous opacities were observed and worsened in some patients with ATTR amyloidosis, supporting the statement that vitreous opacities can occur occasionally in ATTR amyloidosis and lead to visual impairment.
  phenotype_term:
    preferred_term: Vitreous Opacities
    term:
      id: HP:0007710
      label: Peripheral vitreous opacities
- category: Musculoskeletal
  frequency: OCCASIONAL
  name: Carpal Tunnel Syndrome
  notes: Due to amyloid deposition in the wrist
  evidence:
  - reference: PMID:30404120
    supports: SUPPORT
    snippet: One cause for a carpal tunnel syndrome is transthyretin (ATTR) amyloid, which deposits in the carpal tunnel tissue.
    explanation: The article states that ATTR amyloid deposits in the carpal tunnel tissue can cause carpal tunnel syndrome, supporting the statement that ATTR amyloidosis can occasionally cause this musculoskeletal condition.
  - reference: PMID:33443391
    supports: SUPPORT
    snippet: Common orthopaedic manifestations of amyloidosis include carpal tunnel syndrome, trigger finger, spontaneous distal biceps tendon rupture, rotator cuff disease, and lumbar spinal stenosis.
    explanation: The article mentions carpal tunnel syndrome as a common orthopedic manifestation of amyloidosis, supporting the statement that ATTR amyloidosis can occasionally cause this condition due to amyloid deposition in the wrist.
- category: Genitourinary
  frequency: OCCASIONAL
  name: Renal Dysfunction
  notes: Due to amyloid deposition in the kidneys, can lead to proteinuria and renal failure
  evidence:
  - reference: PMID:22537653
    supports: SUPPORT
    snippet: Peripheral neuropathy and cardiomyopathy are broadly described, and insights into disease reveal that kidney impairment and proteinuria are also clinical features.
    explanation: The reference confirms that renal dysfunction, including proteinuria, is a clinical feature of transthyretin amyloidosis (ATTR).
  - reference: PMID:37997196
    supports: SUPPORT
    snippet: Transthyretin cardiac amyloidosis (ATTR-CA) is an infiltrative cardiomyopathy that commonly presents with concomitant chronic kidney disease.
    explanation: The reference supports the statement by indicating that chronic kidney disease, which encompasses renal dysfunction, is commonly associated with transthyretin cardiac amyloidosis (ATTR-CA).
  phenotype_term:
    preferred_term: Renal insufficiency
    term:
      id: HP:0000083
      label: Renal insufficiency
- category: Systemic
  frequency: FREQUENT
  name: Fatigue
  notes: Can be severe and limit activities of daily living
  evidence:
  - reference: PMID:35144512
    supports: SUPPORT
    snippet: Patients often reported problems with mobility, usual activities, pain/discomfort and anxiety/depression, but not with self-care.
    explanation: The literature indicates that systemic amyloidosis, including ATTR, frequently impacts daily life and mobility, which can be associated with fatigue.
  - reference: PMID:31445300
    supports: SUPPORT
    snippet: It is a heterogeneous, multisystem disease with rapidly progressing polyneuropathy (including sensory, motor, and autonomic impairments) and cardiac dysfunction.
    explanation: The literature describes ATTR amyloidosis as a multisystem disease, which can imply the presence of fatigue due to its systemic impact.
  - reference: PMID:33609196
    supports: SUPPORT
    snippet: Amyloid transthyretin (ATTR) amyloidosis is a clinically heterogeneous and fatal disease that results from deposition of insoluble amyloid fibrils in various organs and tissues, causing progressive loss of function.
    explanation: The progressive loss of function in various organs and tissues can lead to severe fatigue, limiting activities of daily living.
  - reference: PMID:35128833
    supports: SUPPORT
    snippet: Amyloidosis is a severe and fatal systemic disease, characterized by an accumulation of amyloid fibrils in various tissues/organs, including nerves, kidneys, gastrointestinal tract, and heart.
    explanation: The systemic nature of ATTR amyloidosis affecting multiple organs can contribute to fatigue.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Neurologic
  name: Sensory Loss
  frequency: FREQUENT
  notes: Loss of sensation, particularly in extremities, due to peripheral nerve damage
  phenotype_term:
    preferred_term: Sensory loss
    term:
      id: HP:0003474
      label: Somatic sensory dysfunction
- category: Neurologic
  name: Numbness and Tingling
  frequency: FREQUENT
  notes: Paresthesias in hands and feet as early manifestation of neuropathy
  phenotype_term:
    preferred_term: Paresthesia
    term:
      id: HP:0003401
      label: Paresthesia
- category: Neurologic
  name: Autonomic Dysfunction
  frequency: FREQUENT
  notes: Includes orthostatic hypotension, gastroparesis, bladder dysfunction
  phenotype_term:
    preferred_term: Autonomic dysfunction
    term:
      id: HP:0012332
      label: Abnormal autonomic nervous system physiology
- category: Cardiovascular
  name: Heart Failure
  frequency: FREQUENT
  notes: Progressive infiltrative cardiomyopathy leading to diastolic and systolic dysfunction
  phenotype_term:
    preferred_term: Heart failure
    term:
      id: HP:0001635
      label: Congestive heart failure
- category: Cardiovascular
  name: Arrhythmias
  frequency: FREQUENT
  notes: Atrial fibrillation, conduction abnormalities, and ventricular arrhythmias
  phenotype_term:
    preferred_term: Cardiac arrhythmia
    term:
      id: HP:0011675
      label: Arrhythmia
- category: Cardiovascular
  name: Orthostatic Hypotension
  frequency: FREQUENT
  notes: Drop in blood pressure upon standing due to autonomic neuropathy
  phenotype_term:
    preferred_term: Orthostatic hypotension
    term:
      id: HP:0001278
      label: Orthostatic hypotension
biochemical:
- name: Serum Transthyretin Levels
  presence: Abnormal (low)
  context: Diagnostic indicator
  evidence:
  - reference: PMID:32356182
    supports: SUPPORT
    snippet: Lower levels of transthyretin and retinol binding protein-4 have been demonstrated in patients with pathogenic mutations of transthyretin either with or without clinical disease.
    explanation: The literature indicates that lower levels of transthyretin are associated with transthyretin amyloidosis, supporting the statement that abnormal (low) serum transthyretin levels can be a diagnostic indicator.
- name: Amyloid P Component
  presence: Elevated
  notes: May be used to monitor disease progression
  evidence:
  - reference: PMID:12394612
    supports: PARTIAL
    snippet: Radiolabelled serum amyloid P component scintigraphy is a non-invasive and quantitative method for imaging amyloid deposits, which produces diagnostic images in most patients with systemic amyloidosis, and can be used repeatedly to monitor the course of the disease.
    explanation: The reference indicates that serum amyloid P component scintigraphy can be used to monitor the course of systemic amyloidosis, but it does not specify whether the levels of amyloid P component are elevated in ATTR amyloidosis.
genetic:
- name: TTR
  association: Pathogenic Variants
  notes: Primary amyloid precursor gene encoding transthyretin, a liver-derived homotetrameric transport protein for thyroxine and retinol. Tetramer instability leads to monomer misfolding and amyloid fibril formation.
  examples:
  - Val30Met
  - Thr60Ala
  frequency: Variable by population
  evidence:
  - reference: PMID:38844302
    supports: SUPPORT
    snippet: More than 140 TTR gene variants have been associated with hATTR, with the Val30Met variant representing the most common worldwide.
    explanation: This reference supports the association of the Val30Met variant with ATTR amyloidosis.
  - reference: PMID:24555660
    supports: SUPPORT
    snippet: A previous study of the amyloidogenic transthyretin mutation TTRV30M in Northern Sweden's endemic area has shown a large variation in carrier frequency and penetrance of the trait within the area.
    explanation: This reference supports the statement about the variable frequency of the Val30Met variant by population.
  - reference: PMID:36941075
    supports: SUPPORT
    snippet: Hereditary transthyretin amyloidosis (hATTR) is a rare autosomal dominant systemic disease with variable penetrance and heterogeneous clinical presentation.
    explanation: This reference supports the statement about the variable frequency of pathogenic variants by population.
- name: APCS
  association: Modifying Factor
  notes: Encodes serum amyloid P component (SAP), a plasma protein that binds and stabilizes amyloid fibrils in deposits, reducing proteolytic clearance.
- name: CLU
  association: Modifying Factor
  notes: Encodes clusterin, an extracellular chaperone present in TTR deposits that modulates fibril localization and clearance.
diagnosis:
- name: Genetic Testing for TTR Mutations
  presence: Positive in hereditary cases
  evidence:
  - reference: PMID:31520266
    supports: SUPPORT
    snippet: Genetic screening allows for the early identification of asymptomatic TTR mutation carriers.
    explanation: The literature supports that genetic testing for TTR mutations is positive in hereditary cases of ATTR amyloidosis.
  - reference: PMID:34076545
    supports: SUPPORT
    snippet: The hereditary transthyretin amyloidosis (ATTRv amyloidosis) is an autosomal dominant genetic disease characterized by amyloid formation in different tissues due to pathogenic variants in the TTR gene.
    explanation: This reference supports that hereditary cases of ATTR amyloidosis involve pathogenic variants in the TTR gene, which can be identified through genetic testing.
  - reference: PMID:37725003
    supports: SUPPORT
    snippet: Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is caused by mutations in the TTR gene, leading to misfolded monomers that aggregate generating amyloid fibrils.
    explanation: This reference supports that genetic testing for TTR mutations is relevant in hereditary cases of ATTR amyloidosis.
- name: Biopsy with Congo Red Staining
  presence: Positive for amyloid deposits
  evidence:
  - reference: PMID:16493520
    supports: SUPPORT
    snippet: Congo red staining according to Romh√°nyi (1971) is a highly specific and sensitive method for early microscopic recognition of amyloidosis.
    explanation: The reference confirms that Congo red staining is a specific and sensitive method for detecting amyloid deposits, supporting the statement.
  - reference: PMID:34637570
    supports: SUPPORT
    snippet: Congo red staining detected amyloid deposits in systemic organs, including the heart, lungs, liver, and kidneys.
    explanation: The reference notes the use of Congo red staining to detect amyloid deposits in various organs, supporting the statement.
  - reference: PMID:28598015
    supports: SUPPORT
    snippet: Congo red staining revealed brilliant red amyloid deposits confirmed by apple-green birefringence within dermal collagen, sweat glands, and arrector pili that engulfed axons.
    explanation: The reference describes the detection of amyloid deposits using Congo red staining, supporting the statement.
  - reference: PMID:33433320
    supports: SUPPORT
    snippet: Light microscopy revealed marked brick-red staining in 11 of 42 samples, 6 moderate and 11 slight staining in the septum of cells, medium and small sized vessel, and apple green double refraction under polarized light microscopy.
    explanation: The reference confirms that Congo red staining is used to detect amyloid deposits in biopsy samples, supporting the statement.
- name: Cardiac MRI
  notes: May show characteristic patterns of amyloid deposition
  evidence:
  - reference: PMID:37553542
    supports: SUPPORT
    snippet: Cardiac amyloidosis shows a particularly characteristic contrast enhancement in cardiac MRI, which mostly begins in the inner (subendocardial) layers of the basal left ventricular (LV) wall and frequently appears to be circular in the cross-sectional view of the left ventricle.
    explanation: The literature confirms that cardiac MRI can show characteristic patterns of amyloid deposition in ATTR amyloidosis.
  - reference: PMID:28728692
    supports: SUPPORT
    snippet: Cardiac magnetic resonance (CMR), with late gadolinium enhancement (LGE) and T1 mapping, is emerging as a reference standard for diagnosis and characterization of cardiac amyloidosis.
    explanation: The literature supports that cardiac MRI (CMR) can show characteristic patterns in ATTR amyloidosis.
- name: Nerve Conduction Studies
  notes: Useful for diagnosing peripheral neuropathy
  evidence:
  - reference: PMID:21463231
    supports: PARTIAL
    snippet: Nonspecific neuropathic features and slight abnormalities in cerebrospinal fluid protein levels and in electrophysiological indices related to nerve conduction led clinicians to initially suspect chronic inflammatory demyelinating polyneuropathy (CIDP) in some patients.
    explanation: The reference indicates that nerve conduction studies can show abnormalities in ATTR amyloidosis, but it does not explicitly state that they are useful for diagnosing peripheral neuropathy specifically in ATTR amyloidosis.
  - reference: PMID:37658177
    supports: PARTIAL
    snippet: Prioritized neuropathy/autonomic endpoints included a modified form of the Neuropathy Impairment Score (NIS + 7) and the Composite Autonomic Symptom Score (COMPASS-31), respectively.
    explanation: The reference mentions neuropathy endpoints but does not provide specific information on the utility of nerve conduction studies for diagnosing peripheral neuropathy in ATTR amyloidosis.
environmental:
- name: None Applicable
  evidence:
  - reference: PMID:21463231
    supports: WRONG_STATEMENT
    snippet: Transthyretin (TTR) Val30Met-associated familial amyloid polyneuropathy (FAP ATTR Val30Met) is the most common form of FAP.
    explanation: The statement that ATTR amyloidosis is 'None Applicable' is incorrect as it is associated with specific conditions such as familial amyloid polyneuropathy.
  - reference: PMID:37907148
    supports: WRONG_STATEMENT
    snippet: CARS (Cardiac Amyloidosis Registry Study) is a multicenter registry established in 2019 that includes patients with transthyretin (ATTR, wild-type and variant) and light chain (AL) cardiac amyloidosis (CA).
    explanation: The statement 'None Applicable' is incorrect because ATTR amyloidosis is a recognized condition included in the Cardiac Amyloidosis Registry Study.
treatments:
- name: Tafamidis
  role: TTR Stabilizer
  description: Helps stabilize transthyretin and prevent amyloid fibril formation.
  evidence:
  - reference: PMID:25872787
    supports: SUPPORT
    snippet: Tafamidis treatment effectively achieved and maintained TTR stabilization and was well tolerated.
    explanation: The study shows that tafamidis effectively stabilizes TTR, supporting the statement that it helps stabilize transthyretin.
  - reference: PMID:31098895
    supports: SUPPORT
    snippet: Tafamidis slowed deterioration of neurological function and maintained health-related quality of life in patients with early-stage ATTR-PN... TTR tetramers were stabilized in nearly all patients.
    explanation: The evidence indicates that tafamidis stabilizes TTR tetramers, supporting the statement.
  - reference: PMID:26800456
    supports: SUPPORT
    snippet: Due to the data on efficacy, tolerability, safety, tafamidis and diflunisal became the first line anti-amyloid treatment in stage 1 TTR-FAP. Both drugs slow progression of the disease.
    explanation: The study supports that tafamidis is effective in stabilizing TTR and preventing amyloid fibril formation.
  - reference: PMID:29962408
    supports: SUPPORT
    snippet: The mutations destabilize the tetramer and/or monomer of TTR, and thus the stabilization of TTR is a key strategy for the treatment of TTR-related amyloidosis.
    explanation: The review supports that stabilizing TTR is crucial, and tafamidis is one of the compounds that achieve this.
  - reference: PMID:34609369
    supports: SUPPORT
    snippet: Several TTR molecule stabilizers were developed successfully... Silencing the TTR gene using different strategies is flourishing.
    explanation: The article states that TTR stabilizers, including tafamidis, have been successfully developed, supporting the statement.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Patisiran
  role: RNA Interference
  description: Reduces production of transthyretin protein to decrease amyloid formation.
  evidence:
  - reference: PMID:30480471
    supports: SUPPORT
    snippet: Patisiran is a novel RNA interference therapeutic that specifically reduces production of both wild-type and mutant transthyretin protein.
    explanation: The abstract clearly states that patisiran reduces the production of transthyretin protein, which aligns with the statement.
  - reference: PMID:37599395
    supports: SUPPORT
    snippet: Novel ribonucleic acid interference (RNAi) therapeutics such as patisiran and inotersen have been shown to benefit neurologic disease course and quality of life in patients with hereditary transthyretin amyloidosis (ATTRv).
    explanation: The abstract mentions that patisiran, as an RNAi therapeutic, benefits patients with hereditary transthyretin amyloidosis, indicating its role in reducing transthyretin protein production.
  - reference: PMID:31131842
    supports: SUPPORT
    snippet: Onpattro, also commonly known as patisiran, is a small interfering RNA (siRNA) molecule packaged within a lipid nanoparticle and is transported into the cell to target transthyretin gene (TTR) messenger mRNA (mRNA) by attaching to its complementary sequence. The target mRNA is degraded and both mutant and wild-type amyloid transthyretin (ATTR) protein production becomes suppressed.
    explanation: The abstract explicitly states that patisiran targets and degrades transthyretin mRNA, thus reducing the production of transthyretin protein.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Inotersen
  role: Antisense Oligonucleotide
  description: Reduces TTR protein production to limit amyloid accumulation.
  evidence:
  - reference: PMID:30561247
    supports: SUPPORT
    snippet: Inotersen/Tegsedi (Akcea Therapeutics, MA, USA) is a second-generation antisense oligonucleotide (ASO) specific for TTR that inhibits production of TTR by the liver.
    explanation: The reference confirms that Inotersen reduces TTR protein production by inhibiting its production in the liver, which aligns with the statement.
  - reference: PMID:37599395
    supports: SUPPORT
    snippet: '''Aims: Novel ribonucleic acid interference (RNAi) therapeutics such as patisiran and inotersen have been shown to benefit neurologic disease course and quality of life in patients with hereditary transthyretin amyloidosis (ATTRv).'
    explanation: The reference supports that Inotersen is used to treat ATTR amyloidosis and implies its role in reducing TTR protein production.
  - reference: PMID:31343345
    supports: SUPPORT
    snippet: Inotersen treatment for ATTR amyloidosis.
    explanation: This reference title directly states that Inotersen is used for the treatment of ATTR amyloidosis, implying its role in reducing TTR protein production.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Liver Transplant
  description: Considered for hereditary cases to reduce production of mutant TTR.
  evidence:
  - reference: PMID:25482846
    supports: SUPPORT
    snippet: Orthotopic liver transplantation (OLT) was implemented as the inaugural disease-modifying therapy because the liver produces the circulating unstable TTR.
    explanation: The literature supports liver transplantation as a therapy to address the production of unstable TTR in hereditary ATTR amyloidosis.
  - reference: PMID:23797140
    supports: SUPPORT
    snippet: Therefore, liver transplantation has become widely accepted as the ultimate curative treatment of this disease in order to prevent the ultimately fatal outcome and ameliorate disabling symptoms.
    explanation: This reference supports the use of liver transplantation to reduce the production of mutant TTR in hereditary cases of ATTR amyloidosis.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
- name: Heart Transplant
  description: May be necessary for those with severe cardiomyopathy.
  evidence:
  - reference: PMID:32304420
    supports: SUPPORT
    snippet: However, the end-stage heart failure is common and HTx could be offered to selected patients, especially if affected by light chain cardiac amyloidosis, to allow to perform the autologous stem cell transplantation after the cardiac transplant.
    explanation: The statement is supported as heart transplantation is mentioned as a treatment for end-stage heart failure in patients with cardiac amyloidosis.
  - reference: PMID:33621542
    supports: SUPPORT
    snippet: Orthotopic heart transplantation (OHT) remains the definitive treatment for patients with end stage heart failure.
    explanation: The statement is supported as orthotopic heart transplantation is identified as a definitive treatment for end-stage heart failure in amyloid cardiomyopathy patients.
  - reference: PMID:34922822
    supports: SUPPORT
    snippet: Heart Transplantation (HT) is a rational therapy for advanced transthyretin cardiac amyloidosis (ATTR-CA)...
    explanation: The statement is supported as heart transplantation is described as a rational therapy for advanced transthyretin cardiac amyloidosis.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
- name: Supportive Care
  description: Symptomatic treatment for neuropathy, heart failure, and gastrointestinal issues.
  evidence:
  - reference: PMID:33099432
    supports: SUPPORT
    snippet: Supportive care manages the symptoms of organ involvement and the side effects of treatment.
    explanation: The reference indicates that supportive care is used to manage the symptoms of organ involvement, which can include neuropathy, heart failure, and gastrointestinal issues.
  - reference: PMID:35235819
    supports: SUPPORT
    snippet: Cardiac amyloidosis (CA) results in symptoms of heart failure, atrial and ventricular arrhythmias, conduction disturbances, and profound autonomic dysfunction.
    explanation: The reference highlights the management of cardiovascular symptoms in cardiac amyloidosis, which is part of supportive care.
  - reference: PMID:35104443
    supports: SUPPORT
    snippet: Systemic amyloidosis is characterized by extracellular deposition of insoluble fibrillar proteins in multiple tissues... The 2 most common forms, light chain (AL) and transthyretin (ATTR) amyloidosis can cause peripheral neuropathy and, rarely, myopathy.
    explanation: The reference discusses the management of neuromuscular complications, including neuropathy, which is part of supportive care.
  - reference: PMID:7588042
    supports: SUPPORT
    snippet: The gastrointestinal manifestations of amyloidosis.
    explanation: The reference discusses gastrointestinal issues related to amyloidosis, which are managed through supportive care.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
review_notes: ATTR amyloidosis is a multisystem disorder caused by deposition of misfolded transthyretin protein. Key diagnostic features are peripheral neuropathy and infiltrative cardiomyopathy. Additional phenotypes across other organ systems are common and reflect the systemic nature of amyloid deposition.
disease_term:
  preferred_term: transthyretin amyloidosis
  term:
    id: MONDO:0007100
    label: familial amyloid neuropathy
classifications:
  harrisons_chapter:
  - classification_value: nervous system disorder
  - classification_value: cardiovascular disorder
  - classification_value: hereditary disease
